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Colitis-associated cancerP21-activated kinases (PAKs) aremultifunctional effectors of Rho GTPaseswith both kinase and scaffolding activ-
ity. Here, we investigated the effects of inﬂammation on PAK1 signaling and its role in colitis-driven carcinogen-
esis. PAK1 and p-PAK1 (Thr423) were assessed by immunohistochemistry, immunoﬂuorescence, and Western
blot. C57BL6/J wildtype mice were treated with a single intraperitoneal TNFα injection. Small intestinal
organoids from these mice and from PAK1-KO mice were cultured with TNFα. NF-κB and PPARγwere analyzed
upon PAK1overexpression and silencing for transcriptional/translational regulation. PAK1expression and activa-
tion was increased on the luminal intestinal epithelial surface in inﬂammatory bowel disease and colitis-
associated cancer. PAK1was phosphorylated upon treatment with IFNγ, IL-1β, and TNFα. In vivo, mice adminis-
tered with TNFα showed increased p-PAK1 in intestinal villi, which was associated with nuclear p65 and NF-κB
activation. p65 nuclear translocation downstream of TNFα was strongly inhibited in PAK1-KO small intestinal
organoids. PAK1 overexpression induced a PAK1–p65 interaction as visualized by co-immunoprecipitation,
nuclear translocation, and increased NF-κB transactivation, all of which were impeded by kinase-dead PAK1.
Moreover, PAK1 overexpression downregulated PPARγ andmesalamine recovered PPARγ through PAK1 inhibi-
tion. On the other hand PAK1 silencing inhibited NF-κB, which was recovered using BADGE, a PPARγ antagonist.
Altogether these data demonstrate that PAK1 overexpression and activation in inﬂammation and colitis-
associated cancer promote NF-κB activity via suppression of PPARγ in intestinal epithelial cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammatory bowel diseases (IBD) such as Crohn's disease (CD) and
ulcerative colitis (UC) are associated with an increased risk of develop-
ing colorectal cancer (CRC). Mesalamine, 5-aminosalicyclic acid (5-
ASA), is an anti-inﬂammatory drug used to treat UC, and epidemiologi-
cal evidence suggests that it has chemopreventive effects [1]. We previ-
ously identiﬁed p-21 activated kinase-1 (PAK1) as a 5-ASA target [2].
PAK1 is a serine/threonine kinase effector of the small Rho GTPases
Rac1/Cdc42 [3], which regulates cytoskeletal dynamics and epithelialperoxisome proliferator associ-
NF-κB, nuclear factor-kappa B;
disease; CAC, colitis-associated
KO, knock out; SIO, small intes-
ntestinal epithelial cells; Rosi,
logy and Hepatology, Medical
a, Austria.
C. Gasche).
. This is an open access article undercell (IEC) migration and homeostasis. Recently, we demonstrated that
PAK1 is overexpressed in IBD and CAC and promotes cell survival path-
ways [4–6]. However, the exact cause and consequence of PAK1 overex-
pression in intestinal inﬂammation have yet to be deﬁned.
Several studies support the notion that canonical NF-κB activation
promotes intestinal tumorigenesis through the upregulation of pro-
inﬂammatory cytokines, proliferation, and cell survival [7–10]. NF-κB
activation is regulated by the transcription factor RelA (p65). At basal
levels, p65 is sequestered in the cytoplasm by its inhibitors IKKα/β
and IκB. Upon pathway activation, IκB is degraded, and p65 translocates
into the nucleus [11]. NF-κB signaling in immune cells drives the ex-
pression of pro-inﬂammatory cytokines such as TNFα or IL-1β, which
subsequently activate NF-κB in IECs thereby promoting cell survival
[12]. In support of this, TNFα-administered NF-κB1−/−mice show in-
creased IEC apoptosis [12]. PAK1 was previously reported to stimulate
NF-κB [13], albeit its exact mechanism within the canonical pathway
is unknown.
Here, we have investigated the effect of PAK1 activation in IECs upon
inﬂammation and its relevance for NF-κB signaling. We observed thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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localization. In IECs, such PAK1 activation induces a p65 interaction and
assists its nuclear translocation through inhibition of PPARγ.
2. Materials and methods
2.1. Animal experiments
9 week old, C57BL/6 mice were provided by Charles River (Margate,
UK) and housed at the University of Liverpool. All procedures were
performed according to UK Home Ofﬁce license guidelines. Mice were
euthanized 1.5 h after receiving an intraperitoneal injection of TNFα
at 0.33 mg/kg body weight. The large (LB) and small bowel (SB) were
dissected and parafﬁn embedded as previously described.
2.2. Cell culture, isolation of small intestinal epithelial organoids, and
reagents
Primary human colon epithelial cells (HCEC-1CT), a generous gift
from Dr. Jerry W. Shay, were cultured as described previously [14].
HCT116 cells were purchased from ATCC. Small intestinal organoids
(SIO) were isolated, from C57BL/6 wild type (WT) and PAK1−/−
(PAK1 KO) mice (purchased from MMRRC UNC, Chapel Hills, NC), and
maintained as previously described [15]. All cells were serum starved
in incomplete medium for 12 h prior to treatment with recombinant
protein. Reagents (Supplementary Table S2) were applied 2–12 h
prior to inﬂammatory cytokines. Cells were harvested at 60–70%
conﬂuency.
2.3. Co-culture
Polymorphonuclear cells (PMN) were isolated, activated, and
cultured using a previously established co-culture system [16]. Brieﬂy,
isolated PMNs were activated using 50 ng/mL phorbol 12-myristate
13-acetate (PMA) at 37 °C for 30 min. PMNs were washed twice with
Ca/Mg free-Hank's buffer salt solution (HBSS), and applied to the
upper chamber of a 0.45 μm Transwell insert in a 1:50 epithelial/PMN
ratio. Following treatment, PMNswere discarded, and colonic epithelial
cells were harvested for western blot analysis.
2.4. Immunohistochemical analysis
Immunohistochemistry (IHC) was performed on 3–5 μm tissue sec-
tions from human samples, andmouse SB or LB [6]. The human samples
were obtained from the Clinical Institute of Pathology at the Medical
University of Vienna. The study was approved by the local ethics com-
mittee. Samples were selected from endoscopic biopsies or surgical
specimens of active IBD and CAC patients. Control specimens were
taken fromnormal colon tissue. CDpatients displayed active colonic dis-
ease, and CAC included both adenoma and invasive tumors.
2.5. Immunoreactivity score
An immunoreactivity score (IRS) was generated by two blinded in-
vestigators. Separate IRSs were generated for the small bowel (SB)
and the large bowel (LB). The SB included villus and crypt epithelial
staining, while the LB included surface and crypt epithelial staining.
The intensity of staining included a score from 0–3, 0 (no staining), 1
(low), 2 (medium), 3 (high). The percentage of positively stainedFig. 1. (A–D). PAK1 is overexpressed and activated in IBD. (A) Human colonic tissue stained for P
surface and crypts in both Crohn's disease (CD), ulcerative colitis (UC), and in tumors of colitis as
normalmucosa (n=6), CD (n=7), and UC (n= 6) at the luminal surface and crypts. PAK1 is o
tissue stained for p-PAK1. In CD andUC, PAK1 activation in epithelial cells is found at themembr
is found within the nuclei and cytoplasm of tumor cells. (D) Inﬂammatory cytokines activate P
either untreated (Con) or treatedwith IFNγ, IL-1β, or TNFα for 5–60min and analyzed for PAK1
activation at 30 min. α-Tubulin was utilized as a loading control.epithelial cells was evaluated on a scale from 0–4, 0 (b1%), 1 (1–10%),
2 (10–50%), 3 (51–80%), and 4 (N80%) in 4 separate ﬁelds of view. The
mean intensity and percentage of positively stained epithelial cells
was multiplied to generate the IRS, and the highest score attainable
was 12. Data shown represent the mean of the 2 scorers' ﬁndings.
2.6. Quantitative real-time PCR
RNA was isolated using TRIzol reagent (Life Technologies). cDNA
synthesiswas carriedout using Thermoscript RT-PCRSystem(Invitrogen)
according to manufacturer's protocol. Quantitative RT-PCR was carried
out in triplicate using Fast SYBR GreenMasterMix with primers (Supple-
mentary Table S3). All data were normalized to the endogenous control
36b4. Relative quantiﬁcation of transcripts were calculated using the
comparative CT method.
2.7. Western blotting (WB) and co-immunoprecipitation (co-IP)
Cells werewashed in PBS and harvested in RIPA buffer for whole cell
lysates. Nuclear and cytoplasmic extracts were collected as previously
described [17]. SIOwere released frommatrigel in ice cold PBS, and cen-
trifuged at 1000 RPM for 5 min. The matrigel was discarded and the
organoids were sonicated for 2–3 s in RIPA buffer. All lysates were har-
vested for 30min on ice and centrifuged at 4 °C for 30min. Protein con-
centration was determined by Bradford assay and measured on an
(Anthos 2010) photometer. For co-immunoprecipitation (co-IP),
750 μg of protein were incubated with 2 μg rabbit or mouse IgG or pri-
mary antibody shaking at 4 °C overnight followed by incubation with
A/G agarose beads for 2 h at room temp. Samples were washed 5×
with PBS and added to SDS sample buffer. For WB, 25–50 μg protein
were added to SDS sample buffer for 10 min at 95 °C. Protein samples
were separated using SDS-PAGE and transferred on a PVDF membrane.
Membranes were blocked in Western blocker solution (Sigma) for 1 h,
and incubatedwith primary antibodies (Supplementary Table S1) over-
night at 4 °C. Protein bands were visualized using IRDye coupled sec-
ondary antibodies and imaged on an Odyssey infrared imaging system
(LI-COR). Images were obtained and densitometry was calculated
using Odyssey application software version 3.0.21.
2.8. Electroporation, PAK1 overexpression, and RNA interference
Transient transfection inHCEC-1CTwas achieved via electroporation
using Amaxa basic nucleofector 2B kit and device for primary mamma-
lian epithelial cells (Lonza) [17]. PAK1 was overexpressed with 5 μg of
pCMV6M-PAK1 (WT-PAK1), a generous gift fromDr. Jonathan Chernoff,
pCMV6M-PAK1K299R (KD-PAK1) (Addgene) or a PCMV6Mempty vec-
tor (EV) (Addgene) for 72 h. PAK1 knockdown using RNA interference
was achieved using 100 nM siPAK1 (Dharmacon) or 100 nM scrambled
siRNA (Santa Cruz) for 48 h.
2.9. Immunoﬂuorescence
HCEC-1CT and SIOwere ﬁxed in 4% paraformaldehyde at room tem-
perature for 30 min and blocked in 0.1% Triton-X-100/2% horse serum
for 1 h. Samples were incubated with primary antibody in 1% BSA/PBS
overnight at 4 °C, then washed and incubated with ﬂuorescent second-
ary antibody for 1 h at room temperature. Samples were washed, dried,
and mounted in medium containing DAPI (Vector Laboratories), and
imaged on an Olympus IX81 or BX51 microscope.AK1. PAK1 expression increases in comparison to normalmucosa at the luminal epithelial
sociated cancer (CAC). (B) Box plots comparemean PAK1 immunoreactivity scores (IRS) in
verexpressed in CAC (n=8). The circle is the outlier from the boxplot. (C) Human colonic
ane, speciﬁcally at the luminal surface, but not in the crypts. In CAC, PAK1 phosphorylation
AK1 in HCEC-1CT. WB of HCEC-1CT RIPA whole cell lysates using 50 μg protein. Cells were
activationwith a p-PAK1Thr 423 antibody. TNFα induced themost profoundeffect in PAK1
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HCEC-1CT cells were transiently transfected with a TkpGL3NF-κB or
PPAR luciferase response element, or co-transfected with scrRNA,
siPAK1, EV, WT-PAK1, or KD-PAK1 and seeded into 24 well plates.
Cells were lysed with a lysis buffer containing 4% Triton X-100, 100 mM
Glycyl-glycine, 100mMMgSO4, and 250mMEGTA for 20min on a shaker
at room temperature. 20 μL of lysate were added into a 96 well plate and
analyzed on a Plate Chameleon V photometer (Hidex) in which 100 μL of
luciferase activity buffer containing 100 mM Glycyl-glycine, 100 mM
MgSO4, 20 mM ATP (Sigma), and 2.5 mM D-luciferin (Sigma) were
injected per well. All measurements were performed using technical
triplicates.
2.11. Statistics
Statistical analysis was performed using SPSS (version 21.0). Metric
outcome variables were compared using univariate analysis of variance
(ANOVA) and Tukey HSD post-hoc tests. RT-PCR data and immunoreac-
tivity scores were analyzed using a 2-tailed t-test. p-Values less than
0.05 were considered signiﬁcant (*p b 0.05, **p b 0.01, ***p b 0.001).
All data are expressed as mean ± standard deviation.
3. Results
3.1. Pro-inﬂammatory cytokines promote PAK1 activation in IEC
PAK1 is associated with gut tumorigenesis [5,18,19] andwe recently
demonstrated its overexpression in IBD and colitis-associated cancer
(CAC) [6]. Here we investigated PAK1 activation and signaling in IBD
and CAC. Normal intestinal mucosa, CD, UC, and CAC samples were
stained with both a PAK1 and p-PAK1 antibody that detects phosphor-
ylation at Thr-423, a residue that is essential for PAK1 activation [20].
In comparison to normal mucosa, total and nuclear PAK1 was over-
expressed at the luminal epithelial surface and crypts in CD and UC, as
well as in tumors of CAC (Fig. 1A–B). PAK1 activationwas absent within
the normal mucosa, and cytoplasmic p-PAK1 levels increased at the lu-
minal intestinal epithelial surface in both UC and CD, but not within the
crypts. CAC tumor samples displayed increased PAK1 phosphorylation
in both the cytoplasm and nucleus (Fig. 1C, Supplementary Fig. S1A).
IFNγ, IL-1β, and TNFα are pro-inﬂammatory cytokines which
contribute to gut inﬂammation in IBD [21]. We investigated their effect
on PAK1 activation in HCEC-1CT cells. IFNγ, IL-1β, and TNFα induced
phosphorylation of PAK1 at Thr-423 within 10 to 30 min (Fig. 1D). Im-
munoﬂuorescence of p-PAK1 revealed cytoplasmic levels of p-PAK1 in-
creased upon TNFα stimulation, and this effect was abolished upon
PAK1 kinase inhibition using IPA-3 (Supplementary Fig. S1B). We further
veriﬁed the speciﬁcity of our p-PAK1 antibody using IPA-3 upon WT-
PAK1 overexpression in the presence of TNFα (Supplementary Fig. S1C).
PAK1 overexpression also resulted in PAK1 auto-phosphorylation. IFNγ,
IL-1β, and TNFα also induced p-PAK1 in the colorectal cancer cell line
HCT116 as early as 5 min peaking within the 30–60 min range (Supple-
mentary Fig. S1D). Accumulation of polymorphonuclear leukocytes
(PMNs) within colonic crypts is a key feature of UC [16]. HCEC-1CT cellsFig. 2. (A–H). PAK1 overexpression regulates NF-kB activation downstream of TNFα in HCEC-1
WT-PAK1 or KD-PAK1 and probed for PAK1 and p65.WT-PAK1 but not KD-PAK1 overexpressio
and Fibrillarin (nucleus). (B) Co-IP of PAK1 (top) and p65 (bottom) probed for PAK1 and p65
co-staining in untreated (Con) and TNFα treated cells. Upper panel p-PAK1, middle panel p6
PAK1 and p65 colocalized upon TNFα. (D) IF of p65 or merged DAPI/p65 in HCEC-1CT. Cells w
accumulation of p65 by TNFα is impeded by p-PAK1 inhibition. The WB veriﬁed p-PAK1 activ
WT-PAK1, and KD-PAK1 overexpression in untreated and TNFα treated cells. Data a
(F) Immunohistochemistry of large bowel (LB) or small bowel (SB) mouse tissue sections staine
paring SB crypt andvilli expression, and LB crypt and surface expression in controlmice (n=3)
in TNFα injectedmice. TNFα increases p-PAK1 expression and p65 (black arrow) nuclear transl
control. Graphs showmean villi p-PAK1 andp65 IRSs (±SD) (n=3)mice per group (t-test, 2 ta
small intestinal organoids (SIO) with or without TNFα. WB of PAK1 protein expression in WTwere co-cultured with freshly isolated PMNs using Transwell inserts.
Total PAK1 expression increased more than two-fold at 60 min (Supple-
mentary Fig. S1E). Taken together, these data demonstrate that pro-
inﬂammatory cytokines and activated PMNs regulate PAK1 activation
and expression in human colonic epithelial cells.
3.2. PAK1 regulates NF-κB activation downstream of TNFα
Our data showed that TNFα, which plays a key role in the pathogen-
esis of IBD [21], and activates canonical NF-κB signaling, induced PAK1
activation. Next, we investigated the role of PAK1 in NF-κB signaling.
Control (EV), WT-PAK1, and KD-PAK1 vectors were overexpressed in
HCEC-1CT and Western blot analysis was performed on cytoplasmic
and nuclear fractions. WT-PAK1 overexpression induced p65 nuclear
translocation in the absence of TNFα, whereas KD-PAK1 did not
(Fig. 2A). Co-immunoprecipitation showed a direct interaction of p65
and PAK1 upon WT-PAK1 overexpression which was reduced upon
KD-PAK1 indicating the importance of auto-phosphorylation of PAK1
for interaction with p65 (Fig. 2B). In the absence of TNFα, immunoﬂuo-
rescence staining of p-PAK1 and p65 revealed localization of both pro-
teins in the cytoplasm. TNFα induced translocation and co-localization
of p-PAK1 and p65 in the nucleus (Fig. 2C). Immunoﬂuorescence in
HCEC-1CT revealed that TNFα activated nuclear translocation of p65
was blocked upon PAK1 kinase inhibition using IPA-3 (Fig. 2D). P-
PAK1 inhibition by IPA-3 was conﬁrmed by Western blot (Fig. 2D).
Western blot analysis supported these observations and demonstrated
that KD-PAK1 abrogated the effect of TNFα on p65nuclear translocation
(Supplementary Fig. S2A). Densitometry of nuclear p65 revealed that
WT-PAK1 overexpressing cells had increased nuclear p65 and were
more sensitive to TNFα in comparison to EV or KD-PAK1 (Supplementary
Fig. S2A). Further, the effect of PAK1 overexpression and the depen-
dence of PAK1 kinase activity on NF-κB transactivation were con-
ﬁrmed using an NF-κB luciferase reporter assay (Fig. 2E). These
data demonstrate that PAK1 overexpression or its activation by
TNFα results in a p-PAK1–p65 interaction, nuclear translocation,
and transcriptional activation of NF-κB.
As the ﬁndings above indicate a concerted action of PAK1 and p65,
we further assessed the distribution of such a PAK1–p65 interaction in
themouse intestine. PAK1 and p-PAK1were expressed in the cytoplasm
within cells of small bowel (SB) villi and of the large bowel (LB) luminal
surface (Fig. 2F). P65 was also cytoplasmic and its localization resem-
bled PAK1 and p-PAK1 in the LB (Fig. 2F). Less than 1%of IECs had nucle-
ar p65. These data suggest thatwithout inﬂammation, PAK1 andp65 are
co-expressed in differentiated IEC of SB villi and LB luminal surface and
canonical NF-κB signaling is not active.
Considering that PAK1 and p65 expression was associated through-
out themouse intestine, we investigated the effect of TNFα on PAK1 ex-
pression and activation in vivo. Mice were i.p. injected with TNFα 1.5 h
before sacriﬁcing and the SB and LB were collected for immunohisto-
chemistry. Total PAK1 expressionwas not altered upon TNFα treatment
(data not shown). We observed a modest increase in p-PAK1 at the LB
epithelial surface (Supplementary Fig. S2B). Nuclear p65, which was
not present in control mice, also increased upon TNFα treatment at
the luminal surface (Supplementary Fig. S2B).CT. (A) WB of HCEC-1CT cytoplasmic and nuclear lysates. Cells were transfected with EV,
n increased nuclear translocation of p65. Loading controls includedα-tubulin (cytoplasm)
demonstrating a PAK1–p65 interaction. (C) Immunoﬂuorescence (IF) of p-PAK1 and p65
5, and lower panel merged p-PAK1/p65 images with or without merged DAPI channel.
ere pre-treated with 10 μM IPA-3 (2 h) followed by 10 ng/mL TNFα for 30 min. Nuclear
ation by TNFα and its inhibition by IPA-3 in HCEC-1CT. (E) NF-κB luciferase assay of EV,
re representative of 3 independent experiments, ANOVA, Tukey HSD; *p b 0.05.
d for PAK1, p-PAK1, or p65. Box plots aremean PAK1 immunoreactivity scores (IRS) com-
mice (t-test, 2 tailed; ***pb 0.001). (G) IHC of p-PAK1and p65within small intestinal tissue
ocation within villi, but not in crypts. PAK1 KOmicewere stained for p-PAK1 as a negative
iled; ***pb 0.001) (H) IF of p65 ormergedDAPI/p65 inwild type (WT) and PAK1KOmouse
or PAK1 KO SIO.
2353K. Dammann et al. / Biochimica et Biophysica Acta 1853 (2015) 2349–2360PAK1 activation upon TNFα treatment within the SB was evenmore
profound (Fig. 2G). This effect was marked towards the villus tip with
an observable gradient along the villus axis. In parallel with PAK1 acti-
vation, a robust accumulation of nuclear p65 was observed, which was
absent in untreated mice. Ex vivo immunoﬂuorescence in smallintestinal organoids (SIO) from WT and PAK1 KO mice conﬁrmed that
PAK1 is required for nuclear p65 translocation following TNFα treat-
ment (Fig. 2H). Complete deletion of PAK1 in PAK1 KO SIO was veriﬁed
byWestern blot (Fig. 2H). Inhibition of PAK1 kinase activity using IPA-3
also impeded nuclear accumulation of p65 on TNFα in SIO (data not
Fig. 2 (continued).
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Fig. 3. (A–F). PAK1 is required for complete activation of NF-κB downstream of IκB in HCEC-1CT. (A) EV, WT-PAK1, or KD-PAK1 overexpressing cells were treated with 10 ng/mL TNFα
(30 min). RIPA lysates were analyzed by WB for PAK1, p-IKKα/β, IKKα, p-IκB-α, and IκBα expression. WT or KD-PAK1 overexpression did not interfere with the degradation of IκB fol-
lowing TNFα treatment. (B)WB of RIPA lysates analyzed for p-p65 and p65. Cellswere treatedwith TNFα or pretreated (12 h)with 10 μM IPA-3 or 20mM5-ASA. Pretreatmentwith IPA-3
or 5-ASA blocked the effect of TNFα on p65. (C)WB of whole cell (RIPA) lysates probed for PAK1, p65, and β-actin. PAK1 knock down by both 5-ASA and siPAK1 blocked total p65 protein
levels. (D) Cells were co-transfected with a NF-κB luciferase reporter and siPAK1 or scrRNA. Pretreatment with 5-ASA and PAK1 knockdown impeded the effect of TNFα on NF-κB tran-
scriptional activation. Data are representative of 3 independent experiments. (E) Relative mRNA expression of RelA upon siPAK1 or scrRNA with or without 5-ASA treatment. PAK1 inhi-
bition increased transcription of RelA. (F) HCEC-1CT cells were treated with 20mM 5-ASA (24 h) with or without the proteasomal inhibitor MG132 (6 h). RIPA lysates were analyzed for
p65 and α-tubulin by WB. 5-ASA inhibits p65 but not upon pretreatment with MG132. All data are representative of 3 independent experiments.
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Fig. 4. (A–G). PAK1modulates a PPARγ/p65 cascade. (A) HCEC-1CT cells were transfected
with a NF-kB luciferase reporter and treated with 1 μM Rosi ± 20mM 5-ASA (24 h). Rosi
and 5-ASA blocked NF-kB transcriptional activity ANOVA, Tukey HSD; ***p b 0.001.
(B) Rosi treated cells were fractionated and analyzed by WB for PAK1 and p65. Rosi
blocked PAK1 and p65 expression. (C) IF of p-PAK1 and PPARγ upon TNFα (30 min)
with or without 20 mM 5-ASA pretreatment (24 h). TNFα resulted in p-PAK1 activation
and PPARγ nuclear export and downregulation which was blocked by 5-ASA. (D) The ef-
fect of EV, WT-PAK1, and KD-PAK1 overexpression on PPARγwas analyzed byWB.α-Tu-
bulin was used as a loading control. Densitometry of PPARγ levels normalized to
α-tubulin, data are mean and SD from 2 independent experiments. (E) RTPCR of PAK1
and PPARγ after EV or WT-PAK1 overexpression with or without 5-ASA treatment
(24 h). PAK1 overexpression blocked PPARγ at the mRNA level, an effect that was recov-
ered by 5-ASA. Data are representative of 3 independent experiments (t-test, 2 tailed;
**p b 0.01). (F) PPAR luciferase reporter assay in PAK1 knock down cells using scrRNA
or siPAK1. siPAK1 activated PPAR transcription, and this effect was recovered upon
0.1 μM BADGE pretreatment (12 h), ANOVA, Tukey HSD; *p b 0.05. (G) NF-kB luciferase
assay in PAK1 knock down cells using scrRNA or siPAK1. Cells were pretreated with
BADGE (12 h) with or without 5-ASA (24 h). BADGE recovered the effect of 5-ASA or
siPAK1 on NF-kB. All data are representative of 3 independent experiments ANOVA,
Tukey HSD; **p b 0.01, ***p b 0.001.
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stream of TNFα in IECs.
3.3. PAK1 is required for complete activation of NF-κB downstream of IκB
in IECs
In order to delineate PAK1's role within canonical NF-κB signaling, we
further investigated the IKKα/β-IκB cascade in HCEC-1CT cells. If PAK1
was upstream of IKKα/β or IκB, PAK1 overexpression would modulate
IkB degradation. Western blot analysis revealed that neither WT-PAK1
nor KD-PAK1 mediated TNFα's effect on IκB degradation (Fig. 3A). PAK1
knockdown (siPAK1) reduced p65 nuclear translocation upon TNFα
treatment, but did not affect IκB phosphorylation or degradation further
suggesting that PAK1 acts downstream of IκB (Supplementary Fig. S3A).
Considering that PAK1 associates with p65 upon TNFα stimulation,
we investigated its effect on p65 stability. PAK1 inhibitors IPA-3 aswell as 5-ASA reduced total p65 protein levels with and without TNFα
(Fig. 3B), although 5-ASA but not IPA-3 inhibited p65 phosphorylation.
Compared to TNF-α treatment, 5-ASA treatment reduced p65 levels
over time upon stimulation with TNF-α and this effect wasmore prom-
inent at 24 h. IPA-3 however, inhibited total p65 levels but did not re-
duce p65 phosphorylation. This suggested that the effect of PAK1
inhibition on p65 is a result of p65 stability, but not phosphorylation.
Mechanistically, 5-ASA reduced PAK1 expression to a similar extent as
siPAK1 and both resulted in reduction of p65 total protein levels
(Fig. 3C) and p65 transcriptional activity (Fig. 3D). 5-ASA did not display
an additive effect to siPAK1 alone suggesting that 5-ASA utilizes PAK1 to
reduce p65. TNFα transactivation of NF-κB was blocked upon 5-ASA,
siPAK1, and their combination. NF-κB transactivation by TNFα was
also blocked by IPA-3 (Supplementary Fig. S3B).
We further investigated whether siPAK1 or 5-ASA reduced p65 at
the transcriptional level. Surprisingly, both siPAK1 and 5-ASA increased
RelAmRNA (Fig. 3E). Inhibition of the proteasomewithMG132, howev-
er, blocked 5-ASA's effect on p65 suggestive that PAK1's role within the
canonical NF-κB pathway is rather posttranslational (Fig. 3F). These
data demonstrate that (1) PAK1 stabilizes p65 protein downstream of
IkB, (2) PAK1 is required for complete activation of NF-κB by TNFα,
and (3) 5-ASA inhibits NF-κB transcriptional activity via inhibition of
total PAK1 in IECs.
3.4. PAK1 modulates a PPARγ/p65 cascade within IECs
Our data indicated that 5-ASA blocks NF-κB in IECs through inhibi-
tion of PAK1. 5-ASA is also a known agonist of PPAR gamma (PPARγ)
[22] and PPARγ polyubiquitinates and degrades p65 [23]. PPARγ is
highly expressed in the gut, and regulates IEC differentiation andmigra-
tion within SB villi [24]. Within the LB, PPARγ activation has anti-
inﬂammatory and chemopreventive effects [22,25].
First, we conﬁrmed that both Rosiglitazone (Rosi; a PPARγ agonist)
and 5-ASA – to a lesser degree – increased PPAR transactivation (data
not shown). Both also blocked NF-κB signaling in our system (Fig. 4A).
Interestingly, Rosi did not add to 5-ASA's effect onNF-κB inhibition, sug-
gesting that both agonists utilize PPARγ activation to inhibit NF-κB
(Fig. 4A). These data were conﬁrmed at the protein level in which
PPARγ activation by Rosi reduced p65 levels in both cytoplasm and nu-
cleus (Fig. 4B). Rosi also reduced PAK1 protein abundance.
Pro-inﬂammatory cytokines, such as TNFα, result in PPARγ degrada-
tion [26], therefore we investigated the TNFα-PAK1-PPARγ cascade via
immunoﬂuorescence. Control HCEC-1CT cells had low levels of p-PAK1,
and PPARγwas present in the nucleus and cytoplasm. TNFα treatment
resulted in PAK1 phosphorylation concomitantwith an apparent reduc-
tion of nuclear and cytoplasmic PPARγ expression (Fig. 4C). 5-ASA
blocked activation of PAK1 and retained PPARγ levels in the presence
of TNFα. These data suggest that TNFα results in activation of PAK1
and in reduction of PPARγ, both of which can be blocked by 5-ASA.
To better understand the interaction between PAK1 and PPARγ, we
overexpressed PAK1 in HCEC-1CT. Total PPARγ protein levels were
reduced upon WT-PAK1 but not upon KD-PAK1 transfection (Fig. 4D).
At the transcriptional level, 5-ASA inhibited PAK1 while increasing
PPARγ mRNA levels (Fig. 4E). WT-PAK1 overexpression decreased
PPARγmRNA levels and5-ASA recovered PPARγ levels. These data dem-
onstrate that PAK1 activation and overexpression downregulate PPARγ
both at the protein andmRNA levels, which can be recovered by 5-ASA.
WT-PAK1 overexpression increased the effect of TNFα on NF-κB
transactivation (as shown in Fig. 2E). If this was a result of PPARγ inhibi-
tion, PPARγ activation should recover this effect. NF-κB luciferase assay
showed that in control cells (EV), Rosi blocked TNFα transactivation of
NF-κB (Supplementary Fig. S4A). Rosi also blocked the effect of WT-
PAK1 on NF-κB transactivation. The synergistic effect of WT-PAK1 and
TNFα on NF-κB transactivation was also reduced upon PPARγ activation
by Rosi. These data were further veriﬁed by Western blot in which Rosi
inhibited nuclear PAK1 and p65 upon TNFα in WT-PAK1 overexpressing
Fig. 5. PAK1 modulates a PPARγ/p65 cascade. (Left)Within normal differentiated IEC, PAK1 activity and expression is low while PPARγ is present in both the cytoplasm and nucleus. Cy-
toplasmic NF-kB is maintained in an inactive state via the sequestration of p65 by IkB. PPARγ further regulates free p65 through E3 ligase activity and proteasomal degradation in the cy-
toplasm. (Middle) In chronic inﬂammation and colitis associated cancer (CAC) PAK1 is hyperactivated while PPARγ is downregulated. Pro-inﬂammatory cytokines such as TNFα induce
PAK1phosphorylation, activation, and nuclear colocalizationwith p65. Activated PAK1 also blocks PPARγ, further increasing the nuclear accumulation of p65 independently of IkB. (Right)
The anti-inﬂammatory drug 5-ASA inhibits PAK1 thereby restoring PPARγ expression, and increasing its activity in inhibiting free p65 in the cytoplasm.
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siPAK1 did not further block transactivation of NF-κB (Supplementary
Fig. S4C). These data support that PAK1 activation and overexpression
activates NF-κB through inhibition of PPARγ.
WT-PAK1overexpression suppressed PPARγ (Fig. 4D&E),whichwas
recovered upon 5-ASA treatment. If inhibition of PAK1 is required for
PPARγ activation, PAK1 knock down should result in PPARγ activation.
In fact, siPAK1 increased PPARγmRNA and its downstream target CD36
(Supplementary Fig. S4D). Moreover, PPARγ and CD36 expression was
increased ﬁve-fold in PAK1-KO SIO (Supplementary Fig. S4E). siPAK1
also induced PPAR transactivation and the PPARγ antagonist BADGE
blocked this effect (Fig. 4F). These data demonstrate that PAK1 inhibi-
tion itself is sufﬁcient to activate PPARγ transcriptional activity.
If PAK1 regulates NF-κB signaling through modulation of PPARγ,
then PPARγ inhibition should impede the effect of PAK1 inhibition in
reducing NF-κB transactivation. As shown in Fig. 3D, 5-ASA, siPAK1,
and 5-ASA in combination with siPAK1 inhibited NF-κB transcriptional
activity. Inhibition of PPARγ with BADGE reduced the effect of 5-ASA
and siPAK1 on NF-κB transactivation (Fig. 4G). Overall these data dem-
onstrate that (1) PAK1 activates NF-κB through suppression of PPARγ,
and (2) activation of PPARγ by 5-ASA (PAK1 inhibition) or PAK1 silenc-
ing downregulate NF-κB.
4. Discussion
Chronic gut inﬂammation triggers the development of CAC. Here we
demonstrate that in colitis PAK1 is overexpressed in IECs although PAK1
activation is limited to the luminal surface. With advancement to CAC,
PAK1 is further overexpressed and phosphorylated throughout the
tumor. PAK1 activation by pro-inﬂammatory cytokines contributes to
canonical NF-κB signaling through inhibition of PPARγ. Mechanistically,
PAK1 increases p65 stability downstream of IkB, and is required for
complete activation of NF-κB by TNFα. 5-ASA, commonly used in the
treatment of IBD, downregulated NF-κB transcriptional activity via
PAK1–p65 inhibition. Indeed, 5-ASA has been shown to activate
PPARγ [22,25] and to inhibit PAK1 [27] and its regular intake reduces
the risk of CAC in UC [28]. Altogether, our data reveal a novel role of
PAK1 for IEC homeostasis during gut inﬂammation.
Pro-inﬂammatory cytokine secretion from immune cells drives
inﬂammation in IBD [21]. Inﬂammatory cytokines such as TNFα werepreviously reported to activate PAK1 in ﬁbroblasts, keratinocytes, mac-
rophages, and endothelial cells [13,29–31]. Here we also demonstrate
phosphorylation of PAK1 by IL-1β and IFNγ in IEC. Although, we did
not investigate the mechanism of PAK1 activation by these cytokines,
upstream activators of PAK1 such as the Rho-GTPases Rac1/Cdc42
may be involved [32–34].
In vivo, in the absence of inﬂammation, PAK1 expression was more
robust at the luminal surface epithelium and in small intestinal villi
than in the crypts. This was surprising as PAK1 phosphorylates
β-catenin, which is predominately located in the proliferative zone at
the base of the crypts [35,36]. Interestingly, p65 expression was also lo-
calized at the luminal surface, supporting that expression of PAK1 and
p65 are associated throughout the intestine. PAK1 expression was
more pronounced within SB villi in comparison to the surface of the
LB epithelium, which may provide a physiological advantage in modu-
lating cytoskeletal rearrangements required for enterocyte migration
along the villus axis. During inﬂammation, PAK1 triggers p65 nuclear
translocation thereby preventing cells from physiological shedding like-
ly through inhibition of apoptosis [12]. This would assist in the restora-
tion of intestinal barrier integrity after intestinal infections. In CAC,
PAK1 is both overexpressed and activated. We modeled PAK1 overex-
pression via WT-PAK1 overexpression in HCEC-1CT, which induced a
PAK1–p65 interaction as well as nuclear translocation of p65, and NF-
κB transactivation in the absence of TNFα. Such activation of p65 has
been shown to delay apoptosis and promote carcinogenesis [8]. More-
over, TNFα-activated NF-κB transactivation was enriched upon overex-
pression ofWT-PAK1 but impeded upon KD-PAK1, suggesting a role for
PAK1 kinase activity in TNFα signaling. We observed subtle differences
between the transcriptional assay and protein data whichmay be an ef-
fect of the speciﬁcity of the two readouts, and a PAK1 speciﬁc role for
NF-kB activation in the nucleus [37]. Regarding the protein data, KD-
PAK1 overexpression could not fully impede nuclear p65 translocation
upon TNF-stimulation, possibly due to PAK1 independent pathways.
Therefore, it is likely that overexpression of KD-PAK1 reduces NF-kB
transactivation more effectively than reducing p65 protein levels. One
limitation to our study is that we did not treat PAK1-KO mice with
TNFα. However, we utilized SIO from PAK1-KO mice which blocked
nuclear translocation of p65 downstream of TNFα. Together, our data
support PAK1 as a critical mediator of NF-κB activation downstream of
TNFα within IEC and suggest that PAK1 overexpression, activation,
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taining NF-κB activity.
TGFβ activated kinase (TAK1) is required for canonical NF-κB activa-
tion primarily through phosphorylation of IKKα and through inducing
IkB degradation [38]. Neither PAK1 overexpression nor knockdown
interfered with the upstream IKKα/IkB cascade, suggesting that
PAK1's effect on p65 is through an alternative pathway separate from
TAK1 and downstream of IkB.
Besides its role in fatty acid oxidation/transport, and increasing insu-
lin sensitivity [39], PPARγ was recently reported to be an E3 ubiquitin
ligase, which induces p65 degradation [23]. 5-ASA acts as a PPARγ ago-
nist and also inhibits PAK1 and NF-κB [22,27,40]. Here we demonstrate
that 5-ASA induced degradation of p65 protein (Fig. 3C) indicative of
PPARγ's E3 ubiquitin ligase activity. Thus, it was imperative to investi-
gate the PAK1/PPARγ axis. In fact, upon pro-inﬂammatory signals (as
observed in IBD), PAK1 activation suppresses PPARγ and contributes
to NF-κB signaling by stabilizing p65. This notion is supported by our
observation that total p65 levels are reduced by both 5-ASA and PAK1
inhibition (IPA-3, siPAK1). TNFα initiates PPARγ recruitment and deg-
radation of p65 in mouse embryonic ﬁbroblasts [23]. In our system,
TNFα increased PAK1 activation concurrent with PPARγ downregula-
tion (Fig. 4C). As PAK1 overexpression inhibits PPARγ at the protein
and transcriptional levels, it is likely that PAK1 itself, or its downstream
targets (JNK or ERK) could phosphorylate PPARγ leading to its nuclear
export and proteasomal degradation [41]. Moreover, PPARγ is known
to regulate its own expression [42], therefore down regulation of
PPARγ at the protein level would result in reduced transcription,
which we also observed in our system (Fig. 4D&E). PAK1 activation or
overexpression could inhibit PPARγ transcription through multiple
pathways. In pluripotent mesenchymal stem cells, TAK1 suppresses
PPARγ via a NF-κB interacting kinase (NIK) cascade [26]. PAK1 activation
of NIK was previously described [43] and may result in PPARγ inhibition.
It is plausible that PAK1 activation and subsequent phosphorylation of
SMART [44], Snail [45], or the estrogen receptor [46] may downregulate
PPARγ [47–49]. Nevertheless, our data implicate PAK1 in modulating a
PPARγ/p65 cascade, which has not previously been reported.
Wedid not study the effect of PAK1 on other PPARs as 5-ASA is a spe-
ciﬁc agonist for PPARγ [22], and only PPARγ but not PPARα or δ induces
p65 degradation [23]. Interestingly, both 5-ASA and Rosiglitazone
inhibited PAK1 (Figs. 3C and 4B). One explanation may be upon ligand
activation, PPARγmay not onlymark p65 but also a PAK1–p65 complex
for proteasomal degradation. 5-ASA also inhibits PAK1 at the mRNA
level which is suggestive of an additional mechanism independent of
PPARγ ligand activation.
We propose that PAK1 is another player in PPARγ/NF-κB cascade
in intestinal epithelial cells (Fig. 5). In differentiated normal IECs,
PPARγ regulates NF-κB through proteasomal degradation of p65.
However, in the presence of inﬂammation or CAC, PAK1 is over-
expressed and activated, whereas PPARγ is suppressed [50]. PAK1
overexpression or activation blocks PPARγ leading to increased
NF-κB transcriptional activation. In addition we further demonstrate
that inhibition of PAK1 by 5-ASA also leads to activation of PPARγ's
E3 ligase activity.
Overall, these ﬁndings support a role for PAK1 in epithelial cell
homeostasis in IBD and CAC. Pharmacological inhibition of PAK1 overex-
pression may recover PPARγ levels and impair the inﬂammatory re-
sponse such as NF-kB activation in IEC.
Supplementary data to this article can be found online at http://dx.
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